Prognostic Value of Three New Biomarkers of Multiple Sclerosis in Patients With Radiologically Isolated Syndrome

N/ACompletedNCT03357887

Centre Hospitalier Universitaire de Nīmes100 enrolled

Overview

To look at the prognostic value of new biomarkers in CSF and serum for characterisation of multiple sclerosis

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Multiple Sclerosis Radiologically Isolated Syndrome

Interventions

Analysis of cerebrospinal fluid and serumOTHER

Analysis of biomarkers in patient biological samples

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion criteria * Patients have given their free consent for use of their samples in research * Patients have at least 2 years of clinical and radiological follow-up data available Exclusion criterion * No follow-up of patients

Locations (1)

CHU Nimes

Nîmes, France

Outcomes

Primary Outcomes

Level of tumour necrosis factor receptor in cerebrospinal fluid

ELISA

Time frame: Baseline

Level of Neurofilament in cerebrospinal fluid

ELISA

Time frame: Baseline

Level of GFAP in cerebrospinal fluid

ELISA

Time frame: Baseline

Level of secreted glycoprotein in cerebrospinal fluid

ELISA

Time frame: Baseline

Secondary Outcomes

Level of tumour necrosis factor receptor in serum

ELISA

Time frame: Baseline

Level of Neurofilament in serum

ELISA

Time frame: Baseline

Level of GFAP in serum

ELISA

Time frame: Baseline

Level of secreted glycoprotein in serum

ELISA

Time frame: Baseline

Comparison of the conversion time according to the threshold value of each biomarker for Radiologically Isolated Syndrome patients

Log-rank test

Time frame: Baseline

Compare prognostic value of all four markers of the high risk criteria (age below 37, male, myelitis).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.